Results 201 to 210 of about 205,535 (299)
Multivariate genetic analysis reveals three distinct pathological dimensions in musculoskeletal disorders. [PDF]
Gong W +8 more
europepmc +1 more source
Abstract The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by ...
Nisa Maria +4 more
wiley +1 more source
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Technology-Driven Ergonomics: A Narrative Review of Innovative Strategies for Preventing Musculoskeletal Disorders in Modern Work Environments. [PDF]
Shakerian M, Salehi A.
europepmc +1 more source
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval +6 more
wiley +1 more source
Ergonomic risk assessment for musculoskeletal disorders in office workers Turkish version, validity and reliability study. [PDF]
Erol E, Arıkan H.
europepmc +1 more source
Aim Intradermal application of lipopolysaccharide (LPS), a Toll‐like receptor 4 agonist, induces a local inflammatory response and is used as a human challenge model to evaluate the pharmacodynamics of investigational medicinal products. While currently applied in a single, parallel‐group setting, alternative within‐subject designs involving repeated ...
Alexandra A. J. Sillé +12 more
wiley +1 more source
The Silent Strain: Grip Strength, and Wrist/Hand Musculoskeletal Disorders among Meat Cutters. [PDF]
Jahangiri H +5 more
europepmc +1 more source
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar +6 more
wiley +1 more source

